Brought to you by 
OpGen gets $10.4mm via PIPE
20 May 2016
Executive Summary
In a first tranche, OpGen Inc. (infectious disease diagnostics) raised $10.4mm through the private sale of 9mm units at $1.14375 (a 7% discount). Lead investors Merck Global Health Innovation and Sabby Management were joined by OpGen management and certain directors. Each unit consists of one common share and one five-year warrant to purchase 0.75 of a share exercisable at $1.3125 per whole share. The company will use the funds for ongoing commercial activities and development of its rapid diagnostics and Acuitas Lighthouse bioinformatics platform. The second closing is expected to occur in mid-June 2016.
Deal Industry
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
OpGen gets $10.4mm via PIPE
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice